Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved the prognosis of mutant lung cancer; however, the clinical application value of TKIs for nonclassical EGFR mutation is unclear, especially for patients with rare uncommon mutations.

中文翻译：

---

具有罕见突变的晚期肺腺癌的阿法替尼治疗反应

表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）改善了突变肺癌的预后；然而，TKI对非经典EGFR突变的临床应用价值尚不清楚，尤其是对于罕见罕见突变的患者。